Acute d-serine treatment produces antidepressant-like effects in rodents

International Journal of Neuropsychopharmacology

Volumn 15, Issue 8, 2012, Pages 1135-1148

  Malkesman, Oz ^a   Austin, Daniel R ^a   Tragon, Tyson ^a   Wang, Gang ^a   Rompala, Gregory ^a   Hamidi, Anahita B ^a   Cui, Zhenzhong ^a   Young, W Scott ^a   Nakazawa, Kazu ^a   Zarate, Carlos A ^b   Manji, Husseini K ^a,c   Chen, Guang ^a,c  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antidepressant; d serine; glutamate; N methyl d aspartate receptor (NMDAR); NR1 knockout

Indexed keywords

DEXTRO SERINE; KETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; SEROTONIN;

ANIMAL EXPERIMENT; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DEPRESSION; EXPERIMENTAL TEST; FEMALE URINE SNIFFING TEST; FORCED SWIMMING TEST; HYPOTHESIS; LEARNED HELPLESSNESS; MALE; MOTOR PERFORMANCE; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RODENT; SEROTONIN RELEASE; SEXUAL BEHAVIOR;

ANALYSIS OF VARIANCE; ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASE TYPE 2; DEPRESSION; DISEASE MODELS, ANIMAL; ESCAPE REACTION; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; FEMALE; HELPLESSNESS, LEARNED; HIPPOCAMPUS; IMMOBILITY RESPONSE, TONIC; KETAMINE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PHENYLENEDIAMINES; RATS; RATS, INBRED WKY; RECEPTORS, N-METHYL-D-ASPARTATE; RNA, MESSENGER; SERINE; SWIMMING;

EID: 84864558985     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711001386     Document Type: Article

References (73)

1. Autry AE, Adachi M, Nosyreva E, Na ES, et al. (2011). NMDA receptor blockade at rest triggers rapid behavioral antidepressant responses. Nature 475, 91-95.
2. Banasr M, Chowdhury GM, Terwilliger R, Newton SS, et al. (2010). Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole. Molecular Psychiatry 15, 501-511.
3. Banasr M, Duman RS (2008). Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biological Psychiatry 64, 863-870.
4. Belmaker RH, Agam G (2008). Major depressive disorder. New England Journal of Medicine 358, 55-68.
5. Billard JM (2008). D-serine signalling as a prominent determinant of neuronal-glial dialogue in the healthy and diseased brain. Journal of Cellular and Molecular Medicine 12, 1872-1884.
6. Bremner JD, Vythilingam M, Vermetten E, Nazeer A, et al. (2002). Reduced volume of orbitofrontal cortex in major depression. Biological Psychiatry 51, 273-279.
7. Cohen JW, Louneva N, Han LY, Hodes G, et al. (2011). Chronic corticosterone exposure alters postsynaptic protein levels of PSD-95, NR1, and synaptopodin in the mouse brain. Synapse 65, 763-770.
8. Cotter D, Mackay D, Landau S, Kerwin R, et al. (2001). Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Archives of General Psychiatry 58, 545-553.
9. Cryan JF, O'Leary OF, Jin SH, Friedland JC, et al. (2004). Norepinephrine-deficient mice lack responses to antidepressant drugs, including selective serotonin reuptake inhibitors. Proceedings of the National Academy of Sciences USA 101, 8186-8191.
10. Dang MT, Yokoi F, Yin HH, Lovinger DM, et al. (2006). Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum. Proceedings of the National Academy of Sciences USA 103, 15254-15259.
11. Davidson ME, Kerepesi LA, Soto A, Chan VT (2009). D-Serine exposure resulted in gene expression changes implicated in neurodegenerative disorders and neuronal dysfunction in male fischer 344 rats. Archives of Toxicology 83, 747-762.
12. De La Garza II R, Mahoney III JJ (2004). A distinct neurochemical profile in WKY rats at baseline and in response to acute stress: implications for animal models of anxiety and depression. Brain Research 1021, 209-218.
13. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, et al. (2010a). A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Archives of General Psychiatry 67, 793-802.
14. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, et al. (2010b). Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. Journal of Clinical Psychiatry 71, 1605-1611.
15. Duman RS (2009). Neuronal damage and protection in the pathophysiology and treatment of psychiatric illness: stress and depression. Dialogues in Clinical Neuroscience 11, 239-255.
16. Dwivedi Y, Rizavi HS, Conley RR, Pandey GN (2006). ERK MAP kinase signaling in post-mortem brain of suicide subjects: differential regulation of upstream raf kinases raf-1 and b-Raf. Molecular Psychiatry 11, 86-98.
17. Dwivedi Y, Rizavi HS, Roberts RC, Conley RC, et al. (2001). Reduced activation and expression of ERK1/2 MAP kinase in the post-mortem brain of depressed suicide subjects. Journal of Neurochemistry 77, 916-928.
18. Dwivedi Y, Rizavi HS, Zhang H, Roberts RC, et al. (2009). Aberrant extracellular signal-regulated kinase (ERK)1/2 signalling in suicide brain: role of ERK kinase 1 (MEK1). International Journal of Neuropsychopharmacology 12, 1337-1354.
19. Einat H, Yuan P, Gould TD, Li J, et al. (2003). The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. Journal of Neuroscience 23, 7311-7316.
20. Fukushima T, Kawai J, Imai K, Toyo'oka T (2004). Simultaneous determination of D-and L-serine in rat brain microdialysis sample using a column-switching HPLC with fluorimetric detection. Biomedical Chromatography 18, 813-819.
21. Haydon PG (2001). GLIA: listening and talking to the synapse. Nature Reviews Neuroscience 2, 185-193.
22. Heresco-Levy U, Javitt DC, Ebstein R, Vass A, et al. (2005). D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biological Psychiatry 57, 577-585.
23. Heresco-Levy U, Vass A, Bloch B, Wolosker H, et al. (2009). Pilot controlled trial of D-serine for the treatment of post-traumatic stress disorder. International Journal of Neuropsychopharmacology 12, 1275-1282.
24. Hermes G, Li N, Duman C, Duman R (2011). Post-weaning chronic social isolation produces profound behavioral dysregulation with decreases in prefrontal cortex synaptic-associated protein expression in female rats. Physiology and Behavior 104, 354-359.
25. Hou C, Jia F, Liu Y, Li L (2006). CSF serotonin, 5-hydroxyindolacetic acid and neuropeptide y levels in severe major depressive disorder. Brain Research 1095, 154-158.
26. Hunsberger J, Austin DR, Henter ID, Chen G (2009). The neurotrophic and neuroprotective effects of psychotropic agents. Dialogues in Clinical Neuroscience 11, 333-348.
27. Hunsberger JG, Machado-Vieira R, Austin DR, Zarate C, et al. (2011). Bax inhibitor 1, a modulator of calcium homeostasis, confers affective resilience. Brain Research 1403, 19-27.
28. Ibrahim L, Diazgranados N, Luckenbaugh DA, Machado-Vieira R, et al. (2011). Rapid decrease in depressive symptoms with an N-methyl-D-aspartate antagonist in ECT-resistant major depression. Progress in Neuropsychopharmacology and Biological Psychiatry 35, 1155-1159.
29. Jiang Z, Belforte JE, Lu Y, Yabe Y, et al. (2010). eIF2alpha phosphorylation-dependent translation in CA1 pyramidal cells impairs hippocampal memory consolidation without affecting general translation. Journal of Neuroscience 30, 2582-2594.
30. Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, et al. (2010). High dose D-serine in the treatment of schizophrenia. Schizophrenia Research 121, 125-130.
31. Kartvelishvily E, Shleper M, Balan L, Dumin E, et al. (2006). Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors. Journal of Biological Chemistry 281, 14151-14162.
32. Krishnan V, Nestler EJ (2008). The molecular neurobiology of depression. Nature 455, 894-902.
33. Lambert G, Johansson M, Agren H, Friberg P (2000). Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Archives of General Psychiatry 57, 787-793.
34. Larkin GL, Beautrais AL (2011). A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. International Journal of Neuropsychopharmacology 14, 1127-1131.
35. Law AJ, Deakin JF (2001). Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12, 2971-2974.
36. Lenz G, Avruch J (2005). Glutamatergic regulation of the p70S6 kinase in primary mouse neurons. Journal of Biological Chemistry 280, 38121-38124.
37. Li N, Lee B, Liu RJ, Banasr M, et al. (2010). mTORdependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329, 959-964.
38. Li N, Liu RJ, Dwyer JM, Banasr M, et al. (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biological Psychiatry 69, 754-761.
39. Maeng S, Hunsberger JG, Pearson B, Yuan P, et al. (2008a). BAG1 plays a critical role in regulating recovery from both manic-like and depression-like behavioral impairments. Proceedings of the National Academy of Sciences USA 105, 8766-8771.
40. Maeng S, Zarate CA, Du J, Schloesser RJ, et al. (2008b). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biological Psychiatry 63, 349-352.
41. Maier SF (1984). Learned helplessness and animal models of depression. Progress in Neuropsychopharmacology and Biological Psychiatry 8, 435-446.
42. Malkesman O, Austin DR, Chen G, Manji HK (2009). Reverse translational strategies for developing animal models of bipolar disorder. Disease Models and Mechanisms 2, 238-245.
43. Malkesman O, Austin DR, Tragon T, Henter ID, et al. (2011). Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Molecular Psychiatry. Published online: 5 July 2011. doi:10.1038/mp.2011.77.
44. Malkesman O, Scattoni ML, Paredes D, Tragon T, et al. (2010). The female urine sniffing test: a novel approach for assessing reward-seeking behavior in rodents. Biological Psychiatry 67, 864-871.
45. Manji HK, Drevets WC, Charney DS (2001). The cellular neurobiology of depression. Nature Medicine 7, 541-547.
46. Mann JJ, Malone KM, Psych MR, Sweeney JA, et al. (1996). Attempted suicide characteristics and cerebrospinal fluid amine metabolites in depressed inpatients. Neuropsychopharmacology 15, 576-586.
47. McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, et al. (2007). Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Research 1127, 108-118.
48. Mothet JP, Parent AT, Wolosker H, Brady RO, et al. (2000). D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proceedings of the National Academy of Sciences USA 97, 4926-4931.
49. Nakanishi S (1992). Molecular diversity of glutamate receptors and implications for brain function. Science 258, 597-603.
50. Nudmamud-Thanoi S, Reynolds GP (2004). The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neuroscience Letters 372, 173-177.
51. O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, et al. (2007). Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berlin) 192, 357-371.
52. Ongur D, Drevets WC, Price JL (1998). Glial reduction in the subgenual prefrontal cortex in mood disorders. Proceedings of the National Academy of Sciences USA 95, 13290-13295.
53. Page ME, Detke MJ, Dalvi A, Kirby LG, et al. (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology (Berlin) 147, 162-167.
54. Panizzutti R, Rausch M, Zurbrugg S, Baumann D, et al. (2005). The pharmacological stimulation of NMDA receptors via co-agonist site: an fMRI study in the rat brain. Neuroscience Letters 380, 111-115.
55. Porsolt RD, Le Pichon M, JalfreM(1977). Depression: a new animal model sensitive to antidepressant treatments. Nature 266, 730-732.
56. Preskorn SH, Baker B, Kolluri S, Menniti FS, et al. (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of Clinical Psychopharmacology 28, 631-637.
57. Price RB, Nock MK, Charney DS, Mathew SJ (2009). Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biological Psychiatry 66, 522-526.
58. Rosenberg D, Kartvelishvily E, Shleper M, Klinker CM, et al. (2010). Neuronal release of D-serine: a physiological pathway controlling extracellular D-serine concentration. FASEB Journal 24, 2951-2961.
59. Ruhe HG, Mason NS, Schene AH (2007). Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Molecular Psychiatry 12, 331-359.
60. Sanacora G, Zarate CA, Krystal JH, Manji HK (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nature Reviews Drug Discovery 7, 426-437.
61. Shaltiel G, Maeng S, Malkesman O, Pearson B, et al. (2008). Evidence for the involvement of the kainate receptor subunit gluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Molecular Psychiatry 13, 858-872.
62. Shopsin B, Friedman E, Gershon S (1976). Parachlorophenylalanine reversal of tranylcypromine effects in depressed patients. Archives of General Psychiatry 33, 811-819.
63. Smith SM, Uslaner JM, Yao L, Mullins CM, et al. (2009). The behavioral and neurochemical effects of a novel d-amino acid oxidase inhibitor compound 8 4H-thieno 3,2-bpyrrole-5-carboxylic acid and D-serine. Journal of Pharmacology and Experimental Therapeutics 328, 921-930.
64. Sweatt JD (2004). Mitogen-activated protein kinases in synaptic plasticity and memory. Current Opinion in Neurobiology 14, 311-317.
65. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, et al. (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. American Journal of Psychiatry 163, 28-40.
66. Tsai GE, Lin PY (2010). Strategies to enhance N-methyl-D-aspartate receptor-mediated neurotransmission in schizophrenia, a critical review and meta-analysis. Current Pharmaceutical Design 16, 522-537.
67. Tsien JZ, Chen DF, Gerber D, Tom C, et al. (1996). Subregion-and cell type-restricted gene knockout in mouse brain. Cell 87, 1317-1326.
68. Yoshikawa M, Nakajima K, Takayasu N, Noda S, et al. (2006). Expression of the mRNA and protein of serine racemase in primary cultures of rat neurons. European Journal of Pharmacology 548, 74-76.
69. Yoshikawa M, Takayasu N, Hashimoto A, Sato Y, et al. (2007). The serine racemase mRNA is predominantly expressed in rat brain neurons. Archives of Histology and Cytology 70, 127-134.
70. Young III WS, Mezey E (2004). Hybridization histochemistry of neural transcripts. Current Protocols in Neuroscience, Chapter 1: Unit 1.3.
71. Yuan P, Zhou R, Wang Y, Li X, et al. (2010). Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. Journal of Affective Disorders 124, 164-169.
72. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry 63, 856-864.
73. Zisook S, Ganadjian K, Moutier C, Prather R, et al. (2008). Sequenced treatment alternatives to relieve depression (STAR*D): lessons learned. Journal of Clinical Psychiatry 69, 1184-1185.